| Year - Ending | Revenue | Operating Income | Net Income |
| Sep-2022 | 4,862 | 1,630 | 1,302 |
| Sep-2021 | 5,632 | 2,482 | 1,871 |
| Sep-2020 | 3,776 | 1,124 | 1,115 |
| Sep-2019 | 3,367 | -10 | -203 |
| Sep-2018 | 3,218 | 508 | -111 |
Hologic, Inc. in brief
Hologic, Inc. is an unlisted company in the Medical Instruments industry, based in Marlborough, Massachusetts, USA. It was founded in 1985. In the year to September 2025 it had sales of $4.1 B and a net profit of $566 M, about 14 cents of profit for every dollar of sales. It employs about 6,944 people and Stephen P. MacMillan is its chief executive. Its largest product and service lines by sales in 2025 were Disposables (64%), Molecular Diagnostics (32%) and Breast Imaging (27%). By market, the largest shares of its 2025 sales came from USA (74%), Europe (14%) and Asia-Pacific (6%).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Hologic, Inc.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
The company was acquired by Blackstone and TPG in 2026.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Hologic, Inc. timeline
- 1985
- 🏁· approximateFounded
- 1994
- 🔔· approximateInitial public offering on Nasdaq as HOLX
- 1995
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2008
- 💰Revenue passed $1 billionFY2008 revenue of $1.7 billion, up from $738 million in FY2007.
- 2013
- •Legal Entity Identifier issuedLEI 549300DYP6F5ZJL0LB74 registered.
- 2021
- 💰Record revenue of $5.6 billionFY2021, the highest of the 19 years on record.
- 💰Record net income of $1.9 billionFY2021, the highest profit of the 12 years on record.
- 🏆Entered the world's top 1,000 companies by market capRanked #973 with $18.7 billion on 1 January 2021, up from #1,122 on 1 January 2020.
- 2026
- 🏆Entered the world's top 500 companies by market capRanked #312 with $16.9 billion on 8 March 2026, up from #1,025 on 5 January 2024.
Events of Hologic, Inc. from Wikidata, SEC EDGAR, the company's financial years, the GLEIF LEI register and our market-cap rankings. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Hologic, Inc.
- Acquisitions and changes
- Taken over: the company reported a change in control and the delisting of its shares to the SEC on 7 April 2026 (Form 8-K).
Market cap history
World rank over time
Rank in USA: #435 (Jan 2020) · #388 (Jan 2021) · #483 (Jan 2022) · #359 (Dec 2022) · #386 (Jul 2023) · #410 (Jan 2024) · #7 (Mar 2026)
Key ratios
- P/E ratio (TTM)
- —
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- 13.2%
- Operating margin
- 17.4%
- Return on equity
- 10.8%
- Liabilities / assets
- 44.0%
- Net debt
- $548M
- Revenue growth
- +1.7%
- R&D / revenue
- 6.1%
- Revenue per employee
- $591 K
- Profit per employee
- $81 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Sep 2025 | $4.1B | +1.7% | $714M | $566M | 13.8% |
| Sep 2024 | $4.0B | -0.0% | $883M | $790M | 19.6% |
| Sep 2023 | $4.0B | -17.1% | $668M | $456M | 11.3% |
| Sep 2022 | $4.9B | -13.7% | $1.6B | $1.3B | 26.8% |
| Sep 2021 | $5.6B | +49.1% | $2.5B | $1.9B | 33.2% |
| Sep 2020 | $3.8B | +12.1% | $1.1B | $1.1B | 29.5% |
| Sep 2019 | $3.4B | +4.6% | $-124M | $-204M | -6.0% |
| Sep 2018 | $3.2B | — | $-238M | $-111M | -3.5% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Sep 2025 | $1.1B | $59M | $998M | $2.49 | — |
| Sep 2024 | $1.3B | $72M | $1.2B | $3.32 | — |
| Sep 2023 | $1.1B | $92M | $959M | $1.83 | — |
| Sep 2022 | $2.1B | $71M | $2.1B | $5.13 | — |
| Sep 2021 | $2.3B | $118M | $2.2B | $7.21 | — |
| Sep 2020 | $897M | $98M | $798M | $4.21 | — |
| Sep 2019 | $650M | $57M | $593M | $-0.76 | — |
| Sep 2018 | $733M | $58M | $675M | $-0.40 | — |
Quarterly results
Latest quarter to Dec 2025: revenue $1.0B (+2.5% on a year earlier), net income $179M. Trailing 12 months to Dec 2025.
SEC filings
- Apr 7, 20268-KCurrent reportMaterial agreement · Agreement ended · Acquisition or disposal completed · Listing notice · Change in control · Directors or officers changed · Bylaws amended · Regulation FD disclosure
- Apr 6, 20268-KCurrent reportDirectors or officers changed · Other events
- Feb 6, 20268-KCurrent reportShareholder vote · Other events
- Jan 29, 202610-QQuarterly report · period to Dec 2025
- Jan 29, 20268-KCurrent reportResults of operations
- Jan 26, 20268-KCurrent reportOther events
- Jan 22, 202610-K/AAnnual report (amended) · period to Sep 2025
- Nov 18, 202510-KAnnual report · period to Sep 2025
- Nov 7, 20258-KCurrent reportDirectors or officers changed
- Nov 3, 20258-KCurrent reportResults of operations
- Oct 21, 20258-KCurrent reportMaterial agreement · Directors or officers changed · Other events
- Sep 19, 20258-KCurrent reportDirectors or officers changed
Official filings of Hologic, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $4.1 B
- Operating income
- $714 M
- Net income
- $566 M
For year ending September-2025 · source: SEC filing
Balance sheet
- Total assets
- $9.0 B
- Total liabilities
- $4.0 B
- Total equity
- $5.0 B
As of September-2025
HOLOGIC - Yearly Revenue and Net Income - in Million USD
HOLOGIC - Quarterly Results Summary - in Million USD
| Quarterly Ending: | Total Revenue | Operating Income | Net Income |
| Dec-2022 | 1,074 | 263 | 187 |
| Sep-2022 | 953 | 170 | 118 |
| Jun-2022 | 1,002 | 229 | 228 |
| Mar-2022 | 1,435 | 594 | 455 |
| Dec-2021 | 1,471 | 637 | 499 |
| Sep-2021 | 1,316 | 445 | 328 |
| Jun-2021 | 1,168 | 362 | 268 |
Balance sheet
Total Assets as on Sep-2022 was 9,071 Million USD.
Total Liabilities as on Sep-2022 was 4,195 Million USD.
Total Equity as on Sep-2022 was 4,876 Million USD.
Top 4 institutional investors in Hologic, Inc.#
| # | Institution | Shares held | Change (shares) | Value | Filed |
|---|---|---|---|---|---|
| 1 | DekaBank Deutsche Girozentrale | 1,475,379 | 0 (0.00%) | $112 M | Aug 5, 2026 |
| 2 | Mizuho Securities USA LLC | 13,455 | 0 (0.00%) | $1 M | Jul 24, 2026 |
| 3 | IFP Advisors, Inc | 54 | -33 (-37.93%) | $0 M | Jul 20, 2026 |
| 4 | Huntington National Bank | 1 | -404 (-99.75%) | $0 M | Aug 13, 2026 |
Mutual funds holding Hologic, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 AltShares Merger Arbitrage ETFWater Island Capital, LLC | 38,727 | $3 M | — | 2.8% | — | Feb 28, 2026 |
| 🇺🇸 AQR Large Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC | 7,943 | $1 M | — | 0.11% | — | Mar 31, 2026 |
| 🇺🇸 Vanguard 500 Index FundThe Vanguard Group, Inc. | 5.70 M | $0 M | — | <0.01% | +0.8% | Jun 30, 2026 |
| 🇺🇸 The Merger FundVirtus Investment Advisers, LLC | 375,385 | $0 M | — | <0.01% | +0.2% | Jun 30, 2026 |
| 🇺🇸 BlackRock Event Driven Equity FundBlackRock Advisors, LLC | 1.77 M | $0 M | — | <0.01% | no change | May 29, 2026 |
| 🇺🇸 Nexpoint Merger Arbitrage FundNexPoint Asset Management, L.P. | 1.47 M | $0 M | — | <0.01% | +1.2% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Index FundThe Vanguard Group, Inc. | 1.25 M | $0 M | — | <0.01% | −0.1% | Jun 30, 2026 |
| 🇺🇸 iShares U.S. Medical Devices ETFBlackRock Fund Advisors | 970,066 | $0 M | — | <0.01% | +1.3% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 1000 Value ETFBlackRock Fund Advisors | 515,257 | $0 M | — | <0.01% | +0.7% | Jun 30, 2026 |
| 🇺🇸 iShares S&P 500 Value ETFBlackRock Fund Advisors | 381,105 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell Mid-Cap Value ETFBlackRock Fund Advisors | 318,653 | $0 M | — | <0.01% | −0.6% | Jun 30, 2026 |
| 🇺🇸 Fidelity SAI Merger Arbitrage FundFidelity Diversifying Solutions LLC | 295,581 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares ESG Aware MSCI USA ETFBlackRock Fund Advisors | 207,094 | $0 M | — | <0.01% | −1.3% | May 31, 2026 |
| 🇺🇸 iShares Core S&P U.S. Value ETFBlackRock Fund Advisors | 189,837 | $0 M | — | <0.01% | +1.9% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total World Stock Index FundThe Vanguard Group, Inc. | 170,622 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 168,658 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 162,940 | $0 M | — | <0.01% | −2.4% | May 31, 2026 |
| 🇺🇸 iShares Russell 1000 ETFBlackRock Fund Advisors | 157,405 | $0 M | — | <0.01% | −0.6% | Jun 30, 2026 |
| 🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC | 138,368 | $0 M | — | <0.01% | no change | May 29, 2026 |
| 🇺🇸 iShares U.S. Healthcare ETFBlackRock Fund Advisors | 117,311 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares Global Healthcare ETFBlackRock Fund Advisors | 105,133 | $0 M | — | <0.01% | −0.1% | Jun 30, 2026 |
| 🇸🇪 Storebrand Global SolutionsStorebrand Asset Management AS | 109,052 | $0 M | — | 0% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC | 100,790 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares MSCI Global Min Vol Factor ETFBlackRock Fund Advisors | 92,622 | $0 M | — | <0.01% | −2.5% | May 31, 2026 |
| 🇺🇸 iShares MSCI ACWI ETFBlackRock Fund Advisors | 72,235 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 61,706 | $0 M | — | <0.01% | +1.2% | Jun 30, 2026 |
| 🇺🇸 500 Index TrustJohn Hancock Variable Trust Advisers LLC | 45,668 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Equity Index PortfolioThe Vanguard Group, Inc. | 50,007 | $0 M | — | <0.01% | +0.7% | Jun 30, 2026 |
| 🇺🇸 Victory 500 Index FundVictory Capital Management Inc. | 52,689 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares MSCI USA Equal Weighted ETFBlackRock Fund Advisors | 39,320 | $0 M | — | <0.01% | +4.7% | May 31, 2026 |
| 🇺🇸 Bridge Builder Tax Managed Small/Mid Cap FundOLIVE STREET INVESTMENT ADVISERS LLC | 41,299 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Ftse Social Index FundThe Vanguard Group, Inc. | 28,338 | $0 M | — | <0.01% | −2.9% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 1000 Value Index FundThe Vanguard Group, Inc. | 32,822 | $0 M | — | <0.01% | +1.3% | May 31, 2026 |
| 🇺🇸 Avantis U.S. Equity ETFAmerican Century ETF Trust | 30,570 | $0 M | — | <0.01% | +1.2% | May 31, 2026 |
| 🇺🇸 Fidelity Enhanced Mid Cap Core ETFFidelity Management & Research Company LLC | 29,948 | $0 M | — | <0.01% | +1.0% | Jun 30, 2026 |
| 🇺🇸 Vanguard Tax-Managed Capital Appreciation FundThe Vanguard Group, Inc. | 26,958 | $0 M | — | <0.01% | −76% | Jun 30, 2026 |
| 🇺🇸 Vanguard Tax-Managed Balanced FundThe Vanguard Group, Inc. | 29,853 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 The Gabelli ABC FundGabelli Funds, LLC | 27,500 | $0 M | — | <0.01% | +45% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Tax Managed Large Cap FundOLIVE STREET INVESTMENT ADVISERS LLC | 27,432 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Six Circles Managed Equity Portfolio U.S. Unconstrained FundJ.P. Morgan Private Investments Inc. | 30,615 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 JNL Multi-Manager Alternative FundJackson National Asset Management, LLC | 25,712 | $0 M | — | <0.01% | +0.1% | Jun 30, 2026 |
| 🇺🇸 iShares Morningstar Mid-Cap Value ETFBlackRock Fund Advisors | 31,250 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares ESG MSCI KLD 400 ETFBlackRock Fund Advisors | 34,443 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇸🇪 Storebrand Global PlusStorebrand Asset Management AS | 29,379 | $0 M | — | 0% | no change | Jun 30, 2026 |
| 🇺🇸 iShares MSCI World ETFBlackRock Fund Advisors | 22,670 | $0 M | — | <0.01% | +15% | May 31, 2026 |
| 🇺🇸 U.S. Sector Rotation FundJohn Hancock Investment Management LLC | 17,868 | $0 M | — | <0.01% | −2.5% | May 31, 2026 |
| 🇺🇸 Siit S&P 500 Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 16,529 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 AVIP Intech U.S. Low Volatility PortfolioCONSTELLATION INVESTMENTS INC | 20,491 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Praxis Small Cap Index FundPraxis Investment Management, Inc. | 11,418 | $0 M | — | <0.01% | +20% | Jun 30, 2026 |
| 🇺🇸 Calvert U.S. Large Cap Core Responsible Index FundCalvert Research and Management | 23,929 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP | 16,873 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇸🇪 Storebrand USAStorebrand Asset Management AS | 17,346 | $0 M | — | 0% | no change | Jun 30, 2026 |
| 🇸🇪 Storebrand Global All CountriesStorebrand Asset Management AS | 15,467 | $0 M | — | 0% | no change | Jun 30, 2026 |
| 🇺🇸 Xtrackers Russell US Multifactor ETFDBX Advisors LLC | 5,269 | $0 M | — | <0.01% | +9.8% | May 29, 2026 |
| 🇺🇸 Vanguard Esg U.S. Stock ETFThe Vanguard Group, Inc. | 12,264 | $0 M | — | <0.01% | −0.1% | May 31, 2026 |
| 🇺🇸 Vanguard S&P 500 Value Index FundThe Vanguard Group, Inc. | 12,575 | $0 M | — | <0.01% | −1.4% | May 31, 2026 |
| 🇺🇸 Global Multi-Strategy FundPrincipal Global Investors, LLC | 12,804 | $0 M | — | <0.01% | +4.1% | May 31, 2026 |
| 🇺🇸 Morgan Stanley Pathway Large Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 8,597 | $0 M | — | <0.01% | +2.0% | May 31, 2026 |
| 🇺🇸 iShares ESG Advanced MSCI USA ETFBlackRock Fund Advisors | 11,769 | $0 M | — | <0.01% | −0.9% | May 31, 2026 |
| 🇺🇸 iShares ESG MSCI USA Leaders ETFBlackRock Fund Advisors | 7,368 | $0 M | — | <0.01% | −1.2% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 1000 Index FundThe Vanguard Group, Inc. | 9,210 | $0 M | — | <0.01% | −1.6% | May 31, 2026 |
| 🇺🇸 Avantis U.S. Mid Cap Equity ETFAmerican Century ETF Trust | 8,128 | $0 M | — | <0.01% | +3.2% | May 31, 2026 |
| 🇺🇸 Siit Large Cap Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 6,700 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Siit Dynamic Asset Allocation FundSEI INVESTMENTS MANAGEMENT CORPORATION | 5,629 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 9,368 | $0 M | — | <0.01% | −8.9% | Jun 30, 2026 |
| 🇺🇸 Franklin U.S. Equity Index ETFFranklin Advisory Services, LLC | 6,369 | $0 M | — | <0.01% | +7.4% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 6,157 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Large Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 9,569 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Six Circles U.S. Unconstrained Equity FundJ.P. Morgan Private Investments Inc. | 5,424 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 AZL S&P 500 Index FundAllianz Investment Management LLC | 9,748 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Calvert U.S. Large Cap Value Responsible Index FundCalvert Research and Management | 10,479 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Calvert U.S. Mid Cap Core Responsible Index FundCalvert Research and Management | 9,625 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Morningstar Value ETFBlackRock Fund Advisors | 8,671 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares Dow Jones U.S. ETFBlackRock Fund Advisors | 9,405 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares MSCI USA Size Factor ETFBlackRock Fund Advisors | 10,133 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 14,057 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇸🇪 SPP Generation 60-talStorebrand Asset Management AS | 10,257 | $0 M | — | 0% | +16% | Jun 30, 2026 |
| 🇸🇪 SPP Generation 70-talStorebrand Asset Management AS | 8,280 | $0 M | — | 0% | no change | Jun 30, 2026 |
| 🇸🇪 SEB USA ExposureSEB Funds AB | 12,259 | $0 M | — | 0% | no change | Jun 30, 2026 |
| 🇺🇸 Xtrackers MSCI USA Selection Equity ETFDBX Advisors LLC | 3,757 | $0 M | — | <0.01% | −5.4% | May 29, 2026 |
| 🇺🇸 Xtrackers MSCI Kokusai Equity ETFDBX Advisors LLC | 2,087 | $0 M | — | <0.01% | +1.7% | May 29, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 1,225 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 iShares ESG Aware MSCI USA Value ETFBlackRock Fund Advisors | 4,002 | $0 M | — | <0.01% | +6.7% | May 31, 2026 |
| 🇺🇸 Victory Growth and Tax Strategy FundVictory Capital Management Inc. | 1,784 | $0 M | — | <0.01% | +55% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 4,494 | $0 M | — | <0.01% | −0.1% | May 31, 2026 |
| 🇺🇸 Invesco Equally-Weighted S&P 500 FundInvesco Advisers, Inc. | 179,059 | $0 M | — | <0.01% | +0.5% | May 31, 2026 |
| 🇺🇸 Invesco S&P 500 Index FundInvesco Advisers, Inc. | 15,799 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Column Mid Cap FundTrust for Professional Managers | 3,968 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Avantis Responsible U.S. Equity ETFAmerican Century ETF Trust | 1,707 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Avantis U.S. Equity FundAmerican Century ETF Trust | 1,983 | $0 M | — | <0.01% | −41% | May 31, 2026 |
| 🇺🇸 Avantis Total Equity Markets ETFAmerican Century ETF Trust | 229 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Avantis U.S. Large Cap Equity ETFAmerican Century ETF Trust | 4,921 | $0 M | — | <0.01% | +3.8% | May 31, 2026 |
| 🇺🇸 Catholic Values Equity FundSEI INVESTMENTS MANAGEMENT CORPORATION | 1,306 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Siit Multi-Asset Real Return FundSEI INVESTMENTS MANAGEMENT CORPORATION | 1,877 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 97 | $0 M | — | <0.01% | −100% | Jun 30, 2026 |
| 🇺🇸 AVIP AB Mid Cap Core PortfolioCONSTELLATION INVESTMENTS INC | 1,110 | $0 M | — | <0.01% | — | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 3,384 | $0 M | — | <0.01% | −2.7% | Jun 30, 2026 |
| 🇺🇸 Thrivent Large Cap Index PortfolioThrivent Financial for Lutherans | 8,425 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Invesco V.I. Equally-Weighted S&P 500 FundInvesco Advisers, Inc. | 12,505 | $0 M | — | <0.01% | +1.1% | Jun 30, 2026 |
| 🇺🇸 Penn Series Index 500 FundPenn Mutual Asset Management, LLC | 3,503 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Hologic, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Jennifer M. SchneidersPresident, Diag. Solutions | Disposal to the company | -41,462 | — | — | 0 | Form 4 |
| filed | Anne M. LiddyGeneral Counsel | Disposal to the company | -28,052 | — | — | 0 | Form 4 |
| filed | Christiana StamoulisDirector | Disposal to the company | -50,526 | — | — | 0 | Form 4 |
| filed | Brandon SchnittkerPresident, GYN Surgical | Disposal to the company | -17,644 | — | — | 0 | Form 4 |
| filed | Essex D. MitchellChief Operating Officer | Disposal to the company | -77,694 | — | — | 0 | Form 4 |
| filed | Karleen Marie ObertonChief Financial Officer | Disposal to the company | -150,735 | — | — | 0 | Form 4 |
| filed | Amy McBride WendellDirector | Disposal to the company | -25,784 | — | — | 0 | Form 4 |
| filed | Martin D. MadausDirector | Disposal to the company | -5,396 | — | — | 0 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Ownership and subsidiaries
Markets and events: Hologic, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2025 | Q1 2026 | $0M |
| Q3 2025 | Q4 2025 | $0M |
| Q2 2025 | Q3 2025 | $35.6M |
| Q1 2025 | Q2 2025 | $200M |
| Q4 2024 | Q1 2025 | $517.3M |
| Q3 2024 | Q4 2024 | $58.3M |
| Q2 2024 | Q3 2024 | $100M |
| Q1 2024 | Q2 2024 | $0M |
| Q4 2023 | Q1 2024 | $676.8M |
| Q3 2023 | Q4 2023 | $211.2M |
| Q3 2023 | Q3 2023 | $113.6M |
| Q2 2023 | Q2 2023 | $50M |
| Q4 2022 | Q1 2023 | $100M |
| Q3 2022 | Q4 2022 | $175.1M |
| Q2 2022 | Q3 2022 | $0M |
| Q1 2022 | Q2 2022 | $200M |
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Hologic, Inc. scorecard#
Passes 11 of the 18 checks that could be worked out: strongest in financial health (4 of 4), weakest in growth (1 of 6). Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth1 of 6
- ✓Revenue grew in the newest year1.7%Revenue up 1.7% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-5.5%-5.5% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-5.5%-5.5% a year against Medical Instruments's median of 5.0% (37 companies).
- ✗Earnings per share grew in the newest year2.49 vs 3.32Diluted EPS 2.49 in fiscal 2025 against 3.32 the year before (report's currency).
- ✗Net income higher than five years earlier$566 M$566 M in fiscal 2025 against $1.1 B in 2020.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
Profitability4 of 6
- ✓Profitable in the newest year$566 MNet income $566 M in fiscal 2025.
- ✓Profitable in each of the last five years5 of 5Profitable in 5 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median17.4%17.4% against Medical Instruments's median of 7.2% (46 companies).
- ✗Return on equity above 15%11.1%11.1% in fiscal 2025.
- ✓Return on invested capital above 10%10.7%10.7% in fiscal 2025.
- ✗Operating margin wider than three years earlier17.4%17.4% in fiscal 2025 against 33.7% in 2022.
Financial health4 of 4
- ✓Short-term assets cover short-term liabilities3.8×Current ratio 3.75 at the end of fiscal 2025.
- ✓Debt below equity0.5×Debt to equity 0.50 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDA0.5×Net debt 0.5 times EBITDA in fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns2 of 2
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year-4.2%Diluted shares down 4.2% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- ✓Free cash flow covers dividends and buybacks$998 MFree cash flow $998 M against $753 M paid out in fiscal 2025.
Worked out from the statements as filed (sec), the medians of Medical Instruments, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Hologic, Inc.'s statements, beside the median of Medical Instruments.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | 17.4% | 7.2% | |
| Net margin | 13.8% | 3.8% | |
| Return on equity | 11.1% | 3.5% | |
| Revenue growth, 3 years a year | -5.5% | 5.0% | |
| Revenue growth | 1.7% | 8.9% | |
| Debt to equity | 0.50× | 0.46× |
6of 9on the Piotroski tests of financial strength
- Free cash flow has been positive 8 years in a row.
- The share count fell 4.2% in the year (buybacks).
Hologic, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Sep 27, 2025 | FY 2024to Sep 28, 2024 | FY 2023to Sep 30, 2023 | FY 2022to Sep 24, 2022 | FY 2021to Sep 25, 2021 | FY 2020to Sep 26, 2020 | FY 2019to Sep 28, 2019 | FY 2018to Sep 29, 2018 | FY 2017to Sep 30, 2017 | FY 2016to Sep 24, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 4,101+1.7%100% | 4,030−0.0%100% | 4,030−17.1%100% | 4,863−13.7%100% | 5,632+49.1%100% | 3,776+12.1%100% | 3,367+4.6%100% | 3,218+5.2%100% | 3,059+8.0%100% | 2,833—100% | |
| Cost of revenue | 1,599+1.8%39.0% | 1,571+1.4%39.0% | 1,549—38.4% | — | — | — | — | 887+0.5%27.6% | 882+16.5%28.8% | 757—26.7% | |
| Gross profit | 2,118−4.9%51.6% | 2,228+7.5%55.3% | 2,072−30.9%51.4% | 2,997−21.0%61.6% | 3,796+70.4%67.4% | 2,228+90.2%59.0% | 1,171−31.0%34.8% | 1,697+4.7%52.7% | 1,621+3.7%53.0% | 1,563—55.2% | |
| Research and development | 248−9.0%6.1% | 273−7.3%6.8% | 294+3.8%7.3% | 283+2.6%5.8% | 276+24.2%4.9% | 223−4.2%5.9% | 232+6.2%6.9% | 219−6.1%6.8% | 233+0.3%7.6% | 232—8.2% | |
| Selling and marketing | 621+6.0%15.1% | 585−1.6%14.5% | 595−5.6%14.8% | 630+12.3%13.0% | 561+15.8%10.0% | 485−14.2%12.8% | 565+3.7%16.8% | 545+9.2%16.9% | 499+20.1%16.3% | 415—14.7% | |
| General and administrative | 449+9.7%11.0% | 409+4.3%10.2% | 392−3.8%9.7% | 408−5.9%8.4% | 433+21.8%7.7% | 356r356+7.0%9.4% | 332−9.2%9.9% | 366+6.6%11.4% | 343+28.4%11.2% | 267—9.4% | |
| Operating expenses | 1,404+4.3%34.2% | 1,345−4.1%33.4% | 1,403+3.4%34.8% | 1,357+3.2%27.9% | 1,316+17.2%23.4% | 1,123−13.3%29.7% | 1,295−33.1%38.4% | 1,935+671%60.1% | 251−75.3%8.2% | 1,015—35.8% | |
| Operating income | 714−19.1%17.4% | 883+32.0%21.9% | 668−59.2%16.6% | 1,640−33.9%33.7% | 2,480+124%44.0% | 1,105—29.3% | −124—−3.7% | −238−117%−7.4% | 1,370+150%44.8% | 549—19.4% | |
| Interest and finance income | 74−31.6%1.8% | 109−9.8%2.7% | 121+834%3.0% | 13+821%0.3% | 1.4−67.4%0.0% | 4.3−6.5%0.1% | 4.6−27.0%0.1% | 6.3+65.8%0.2% | 3.8+443%0.1% | 0.7—0.0% | |
| Interest expense and finance costs | 117−4.1%2.9% | 122+9.9%3.0% | 111+16.8%2.8% | 95+1.6%2.0% | 94−19.7%1.7% | 117−17.3%3.1% | 141−5.3%4.2% | 149−2.9%4.6% | 153−1.4%5.0% | 155—5.5% | |
| Other non-operating income (expense) | 9.6—0.2% | −4.1—−0.1% | −1.7−106%−0.0% | 31—0.6% | −5.4−159%−0.1% | 9.1+194%0.2% | 3.1−59.2%0.1% | 7.6−41.1%0.2% | 13−51.5%0.4% | 27—0.9% | |
| Income before tax | 681−21.3%16.6% | 865+28.0%21.5% | 676−57.4%16.8% | 1,588−32.7%32.7% | 2,361+136%41.9% | 1,002—26.5% | −258—−7.7% | −419−134%−13.0% | 1,231+196%40.2% | 415—14.7% | |
| Income tax | 116+52.8%2.8% | 76−65.7%1.9% | 220−23.1%5.5% | 286−41.8%5.9% | 491—8.7% | −109—−2.9% | −54—−1.6% | −307−165%−9.5% | 475+462%15.5% | 85—3.0% | |
| Net income including minority interests | 566−28.3%13.8% | 790+73.1%19.6% | 456−65.0%11.3% | 1,302−30.4%26.8% | 1,870+68.4%33.2% | 1,111—29.4% | −204—−6.0% | −111—−3.5% | — | — | |
| Minority interests' share of net income | — | — | 0—0.0% | 0—0.0% | −1.8—−0.0% | — | — | — | — | — | |
| Net income attributable to shareholders | 566−28.3%13.8% | 790+73.1%19.6% | 456−65.0%11.3% | 1,302−30.4%26.8% | 1,872+67.8%33.2% | 1,115—29.5% | −204—−6.0% | −111−115%−3.5% | 756+128%24.7% | 331—11.7% | |
| Earnings per share, basic | 2.50−25.4%— | 3.35+81.1%— | 1.85−64.3%— | 5.18−28.8%— | 7.28+71.7%— | 4.24—— | -0.76—— | -0.40−115%— | 2.70+129%— | 1.18—— | |
| Earnings per share, diluted | 2.49−25.0%— | 3.32+81.4%— | 1.83−64.3%— | 5.13−28.8%— | 7.21+71.3%— | 4.21—— | -0.76—— | -0.40−115%— | 2.64+128%— | 1.16—— | |
| Shares, weighted average (basic) | 226−4.1%— | 236−4.5%— | 247−1.9%— | 252−2.1%— | 257−2.2%— | 263−2.5%— | 269−2.1%— | 275−1.7%— | 280−0.1%— | 280—— | |
| Shares, weighted average (diluted) | 228−4.2%— | 238−4.5%— | 249−2.0%— | 254−2.3%— | 260−1.9%— | 265−1.8%— | 269−2.1%— | 275−3.7%— | 286−0.2%— | 286—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 1,960−9.3%21.7% | 2,160−20.7%23.6% | 2,723+16.4%29.8% | 2,340+99.9%25.8% | 1,170+66.9%13.1% | 701+16.5%9.7% | 602−9.7%9.3% | 667+23.3%9.2% | 541−1.4%6.8% | 548—7.5% | |
| Short-term investments | 243+40.3%2.7% | 173—1.9% | 0—0.0% | — | — | — | — | — | — | 0—0.0% | |
| Receivables | 601+0.1%6.7% | 600−4.0%6.6% | 626+1.3%6.8% | 618−34.5%6.8% | 943−8.4%10.6% | 1,029+58.6%14.3% | 649+12.0%10.1% | 579+8.6%8.0% | 534+19.4%6.7% | 447—6.1% | |
| Inventory | 679−0.1%7.5% | 680+10.1%7.4% | 618−1.0%6.8% | 624+24.4%6.9% | 501+26.9%5.6% | 395−11.2%5.5% | 445+15.8%6.9% | 384+15.8%5.3% | 332+20.7%4.2% | 275—3.8% | |
| Other current assets | 152−2.7%1.7% | 156−10.9%1.7% | 175−24.5%1.9% | 232−56.1%2.6% | 529+804%5.9% | 59−6.8%0.8% | 63—1.0% | — | — | — | |
| Current assets | 3,668−4.1%40.7% | 3,823−8.6%41.8% | 4,185+8.4%45.8% | 3,862+21.9%42.6% | 3,169+42.6%35.5% | 2,222+23.9%30.9% | 1,793+4.1%27.8% | 1,723+16.5%23.8% | 1,479+11.5%18.5% | 1,327—18.1% | |
| Property, plant and equipment | 560+4.1%6.2% | 538+4.0%5.9% | 517+7.4%5.7% | 482−14.7%5.3% | 565+14.9%6.3% | 492+4.4%6.8% | 471−1.5%7.3% | 478+1.1%6.6% | 473r491+4.6%5.9% | 452r460—6.2% | |
| Right-of-use (leased) assets | 94+2.1%1.0% | 92+47.0%1.0% | 63−9.0%0.7% | 69−17.6%0.8% | 84+3.6%0.9% | 81—1.1% | 0—0.0% | — | — | — | |
| Goodwill | 3,641+5.7%40.4% | 3,443+4.9%37.6% | 3,281+1.4%35.9% | 3,237−1.4%35.7% | 3,282+23.5%36.8% | 2,658+3.7%36.9% | 2,564+1.2%39.8% | 2,533−20.1%35.0% | 3,171+13.1%39.7% | 2,803—38.3% | |
| Other intangible assets | 589−30.3%6.5% | 845−5.0%9.2% | 889−30.6%9.7% | 1,281−22.8%14.1% | 1,659+26.9%18.6% | 1,308−10.4%18.2% | 1,460−39.1%22.7% | 2,399−13.5%33.2% | 2,772r2,742+4.9%34.7% | 2,643—36.1% | |
| Long-term investments | 0−100%0.0% | 96—1.1% | 0—0.0% | — | — | — | — | — | — | — | |
| Total assets | 9,015−1.5%100% | 9,156+0.2%100% | 9,139+0.8%100% | 9,071+1.7%100% | 8,920+24.0%100% | 7,196+11.7%100% | 6,442−10.9%100% | 7,231−9.4%100% | 7,980+9.1%100% | 7,317—100% | |
| Accounts payable | 193−5.1%2.1% | 204+16.3%2.2% | 175−11.4%1.9% | 198−8.4%2.2% | 216+20.7%2.4% | 179−4.1%2.5% | 187−3.0%2.9% | 192+15.4%2.7% | 167+6.2%2.1% | 157—2.1% | |
| Debt due within a year | 2.9−92.3%0.0% | 38−86.9%0.4% | 287+1813%3.1% | 15−95.2%0.2% | 313−3.7%3.5% | 325+19.7%4.5% | 271−54.7%4.2% | 600−47.9%8.3% | 1,151+289%14.4% | 296—4.0% | |
| Current liabilities | 977−5.8%10.8% | 1,037−14.1%11.3% | 1,207+28.8%13.2% | 938−29.3%10.3% | 1,327+7.1%14.9% | 1,239+15.8%17.2% | 1,070−23.7%16.6% | 1,403−24.8%19.4% | 1,866+107%23.4% | 902—12.3% | |
| Long-term debt | 2,505+0.3%27.8% | 2,497−1.3%27.3% | 2,531−9.9%27.7% | 2,808+3.5%31.0% | 2,712−0.1%30.4% | 2,714−2.5%37.7% | 2,784+2.9%43.2% | 2,705+24.5%37.4% | 2,172−28.8%27.2% | 3,049—41.7% | |
| Lease liabilities (non-current) | 79−5.4%0.9% | 84+78.1%0.9% | 47−12.5%0.5% | 54−18.6%0.6% | 66+0.8%0.7% | 66—0.9% | 0—0.0% | — | — | — | |
| Retained earnings | 3,412+19.9%37.8% | 2,846+38.4%31.1% | 2,056+28.5%22.5% | 1,600+436%17.6% | 298—3.3% | −1,573—−21.9% | −2,689—−41.7% | −2,494—−34.5% | −2,383—−29.9% | −3,138—−42.9% | |
| Shareholders' equity | 5,048−1.6%56.0% | 5,130+2.3%56.0% | 5,017+2.9%54.9% | 4,876+15.6%53.8% | 4,219+55.9%47.3% | 2,705+27.9%37.6% | 2,116−12.9%32.8% | 2,429−12.8%33.6% | 2,785+30.0%34.9% | 2,143—29.3% | |
| Minority interests | — | — | — | — | 0−100%0.0% | 2.1—0.0% | 0—0.0% | — | — | — | |
| Total equity | 5,048−1.6%56.0% | 5,130+2.3%56.0% | 5,017+2.9%54.9% | 4,876+15.6%53.8% | 4,219+55.8%47.3% | 2,707+28.0%37.6% | 2,116−12.9%32.8% | 2,429−12.8%33.6% | 2,785—34.9% | — | |
| Total liabilities and equity | 9,015−1.5%100% | 9,156+0.2%100% | 9,139+0.8%100% | 9,071+1.7%100% | 8,920+24.0%100% | 7,196+11.7%100% | 6,442−10.9%100% | 7,231−9.4%100% | 7,980+9.1%100% | 7,317—100% | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 300−3.0%7.3% | 309−4.5%7.7% | 323−24.8%8.0% | 430+5.7%8.8% | 407+8.2%7.2% | 376−18.8%10.0% | 463−3.6%13.8% | 480+6.9%14.9% | 449−3.5%14.7% | 465—16.4% | |
| Share-based compensation | 84+2.4%2.1% | 82+3.4%2.0% | 80+19.3%2.0% | 67+2.6%1.4% | 65−22.0%1.2% | 83+34.4%2.2% | 62−4.6%1.8% | 65−4.7%2.0% | 68+4.3%2.2% | 65—2.3% | |
| Cash from operating activities | 1,057−17.7%25.8% | 1,285+22.3%31.9% | 1,051−50.5%26.1% | 2,126−8.8%43.7% | 2,330+160%41.4% | 897+38.0%23.7% | 650−11.4%19.3% | 733+8730%22.8% | 8.3−99.0%0.3% | 798r787—28.2% | |
| Capital expenditure | −59—−1.4% | −72—−1.8% | −92—−2.3% | −71—−1.5% | −118r−97—−2.1% | −98—−2.6% | −57—−1.7% | −58—−1.8% | −58—−1.9% | −47—−1.7% | |
| Intangible assets bought | −15—−0.4% | −10—−0.2% | 0—0.0% | 0—0.0% | −6.5—−0.1% | 0—0.0% | −4.5—−0.1% | 0—0.0% | — | — | |
| Acquisitions, net of cash acquired | −322—−7.8% | −297—−7.4% | −5.0—−0.1% | −159—−3.3% | −1,165—−20.7% | −119—−3.2% | −111—−3.3% | −77—−2.4% | −1,558—−50.9% | 0—0.0% | |
| Cash from investing activities | −483—−11.8% | −781—−19.4% | −152—−3.8% | −206—−4.2% | −1,330—−23.6% | −142—−3.7% | −281—−8.3% | −195−168%−6.1% | 286—9.3% | −68—−2.4% | |
| Debt issued | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Debt repaid | — | — | — | — | — | — | −1,463—−43.4% | −1,359—−42.2% | −84—−2.8% | −75—−2.6% | |
| Shares bought back | −753—−18.4% | −835—−20.7% | −475—−11.8% | −542—−11.1% | −410—−7.3% | −654—−17.3% | −200—−5.9% | −276—−8.6% | −200—−6.5% | −250—−8.8% | |
| Cash from financing activities | −777—−19.0% | −1,109—−27.5% | −483—−12.0% | −756—−15.5% | −530—−9.4% | −660—−17.5% | −432—−12.8% | −405—−12.6% | −309—−10.1% | −671r−660—−23.7% | |
| Exchange-rate effect on cash | 2.1−76.4%0.1% | 8.9+2867%0.2% | 0.3−94.8%0.0% | 5.8—0.1% | −1.7−141%−0.0% | 4.1—0.1% | −2.2—−0.1% | −6.8−193%−0.2% | 7.3—0.2% | −2.0—−0.1% | |
| Change in cash | −201—−4.9% | −596−243%−14.8% | 416−64.4%10.3% | 1,169+149%24.0% | 469+373%8.3% | 99—2.6% | −65−151%−1.9% | 126—3.9% | −7.8−114%−0.3% | 57—2.0% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Dec 27, 2025 | Q1 FY2026to Dec 27, 2025 | Q4 FY2025to Sep 27, 2025 | Q3 FY2025to Jun 28, 2025 | Q2 FY2025to Mar 29, 2025 | Q1 FY2025to Dec 28, 2024 | Q4 FY2024to Sep 28, 2024 | Q3 FY2024to Jun 29, 2024 | Q2 FY2024to Mar 30, 2024 | Q1 FY2024to Dec 30, 2023 | Q4 FY2023to Sep 30, 2023 | Q3 FY2023to Jul 1, 2023 | Q2 FY2023to Apr 1, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 4,127+2.2%100% | 1,048+2.5%100% | 1,050*+6.2%100% | 1,024+1.2%100% | 1,005−1.2%100% | 1,022+0.9%100% | 988*+4.5%100% | 1,011+2.7%100% | 1,018−0.8%100% | 1,013—100% | 945*—100% | 984—100% | 1,027—100% | |
| Cost of revenue | — | 418+6.5%39.9% | — | — | — | 392+27.6%38.4% | — | — | 309+5.6%30.3% | 307—30.3% | 670*—70.9% | 291—29.6% | 292—28.5% | |
| Gross profit | 2,124−5.2%51.5% | 586+1.0%56.0% | 584*+4.6%55.6% | 577+2.9%56.3% | 377−30.4%37.5% | 581+2.3%56.8% | 558*+11.5%56.4% | 560+52.5%55.4% | 542−7.4%53.3% | 568—56.0% | 500*—52.9% | 368—37.3% | 586—57.1% | |
| Research and development | 249−6.7%6.0% | 61+0.3%5.8% | 65*−3.3%6.2% | 61−4.2%6.0% | 62−17.6%6.1% | 60−9.7%5.9% | 67*−7.7%6.8% | 64−11.7%6.3% | 75+0.8%7.3% | 67—6.6% | 73*—7.7% | 73—7.4% | 74—7.2% | |
| Selling and marketing | 609+1.1%14.8% | 155−6.7%14.8% | 148*+1.2%14.1% | 152+4.0%14.9% | 154+7.1%15.4% | 166+11.6%16.3% | 146*+4.7%14.8% | 146−2.3%14.5% | 144+1.3%14.2% | 149—14.7% | 140*—14.8% | 150—15.2% | 142—13.9% | |
| General and administrative | 461+11.6%11.2% | 128+10.5%12.2% | 115*+11.2%10.9% | 99+5.4%9.7% | 120+19.2%11.9% | 116+3.5%11.3% | 103*+11.1%10.4% | 94+4.2%9.3% | 100−0.4%9.9% | 112—11.0% | 93*—9.8% | 90—9.2% | 101—9.8% | |
| Operating expenses | 1,402+5.7%34.0% | 349−0.4%33.3% | 347*+5.8%33.0% | 322+1.8%31.5% | 384+15.8%38.2% | 351−5.0%34.3% | 328*−10.9%33.2% | 316−13.6%31.3% | 332+5.8%32.6% | 369—36.5% | 368*—38.9% | 366—37.2% | 314—30.6% | |
| Operating income | 722−21.1%17.5% | 237+3.1%22.6% | 237*+3.0%22.6% | 255+4.3%24.9% | −7.0−103%−0.7% | 230+15.9%22.5% | 230*+73.6%23.3% | 244+17329%24.1% | 210−22.7%20.7% | 198—19.6% | 133*—14.0% | 1.4—0.1% | 272—26.5% | |
| Interest and finance income | 70−33.4%1.7% | 20−18.6%1.9% | 19*−33.5%1.8% | 16−42.3%1.6% | 15−37.9%1.5% | 24−13.3%2.4% | 28*−20.9%2.9% | 28−12.6%2.8% | 24−23.8%2.4% | 28—2.8% | 36*—3.8% | 33—3.3% | 32—3.1% | |
| Interest expense and finance costs | — | 28−9.5%2.6% | — | 29−9.4%2.8% | 29−9.9%2.9% | 31+17.3%3.0% | 32*+13.5%3.2% | 32+15.2%3.2% | 32+18.8%3.2% | 26—2.6% | 28*—3.0% | 28—2.8% | 27—2.6% | |
| Other non-operating income (expense) | −14−148%−0.3% | 0.6−97.5%0.1% | 0*—0.0% | −7.1−3650%−0.7% | −7.3−178%−0.7% | 24—2.3% | −4.9*−192%−0.5% | 0.2−96.6%0.0% | 9.4+224%0.9% | −8.8—−0.9% | 5.3*—0.6% | 5.9—0.6% | 2.9—0.3% | |
| Income before tax | 663−28.0%16.1% | 230−7.2%21.9% | 227*+2.5%21.6% | 235−2.4%23.0% | −29−113%−2.8% | 248+29.4%24.2% | 222*+52.2%22.4% | 241+1889%23.8% | 212−24.3%20.8% | 191—18.9% | 146*—15.4% | 12—1.2% | 279—27.2% | |
| Income tax | 120−32.5%2.9% | 51+8.8%4.8% | 40*−7.0%3.8% | 40−13.2%3.9% | −11−127%−1.1% | 47—4.6% | 43*−21.8%4.4% | 46−12.2%4.6% | 42−31.6%4.1% | −55—−5.4% | 55*—5.8% | 53—5.3% | 61—5.9% | |
| Net income attributable to shareholders | 544−26.9%13.2% | 179−10.9%17.1% | 187+4.8%17.8% | 195+0.2%19.0% | −17−110%−1.7% | 201−18.5%19.7% | 179+97.1%18.1% | 195—19.2% | 170−22.2%16.7% | 247—24.3% | 91—9.6% | −41—−4.1% | 219—21.3% | |
| Earnings per share, basic | — | 0.80−8.0%— | — | 0.87+4.8%— | -0.08−111%— | 0.87−15.5%— | — | 0.83—— | 0.72−18.2%— | 1.03—— | — | -0.16—— | 0.88—— | |
| Earnings per share, diluted | — | 0.79−9.2%— | — | 0.86+4.9%— | -0.08−111%— | 0.87−15.5%— | — | 0.82—— | 0.72−17.2%— | 1.03—— | — | -0.16—— | 0.87—— | |
| Shares, weighted average (basic) | 224−2.6%— | 224−2.6%— | — | 224−4.4%— | 226−4.3%— | 230−3.5%— | — | 235−5.0%— | 236−4.8%— | 239—— | — | 247—— | 248—— | |
| Shares, weighted average (diluted) | 226−2.7%— | 226−2.7%— | — | 225−4.7%— | 226−5.0%— | 232−3.4%— | — | 236−4.2%— | 238−4.9%— | 240—— | — | 247—— | 250—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 2,168—23.6% | 2,168+21.7%23.6% | 1,960−9.3%21.7% | 1,735−28.9%19.7% | 1,430−34.4%16.7% | 1,782−7.8%20.4% | 2,160−20.7%23.6% | 2,439−11.8%27.4% | 2,180−15.6%25.0% | 1,932—22.8% | 2,723—29.8% | 2,765—29.6% | 2,582—27.3% | |
| Short-term investments | 197—2.1% | 197+3.2%2.1% | 243+40.3%2.7% | 144—1.6% | 192—2.2% | 191—2.2% | 173—1.9% | — | — | — | 0—0.0% | — | — | |
| Receivables | 584—6.4% | 584−7.5%6.4% | 601+0.1%6.7% | 609−3.1%6.9% | 644−0.4%7.5% | 631−5.9%7.2% | 600−4.0%6.6% | 629−8.5%7.1% | 647−9.4%7.4% | 671—7.9% | 626—6.8% | 687—7.4% | 714—7.6% | |
| Inventory | 689—7.5% | 689−2.6%7.5% | 679−0.1%7.5% | 714+7.2%8.1% | 717+10.4%8.4% | 707+11.6%8.1% | 680+10.1%7.4% | 666−2.1%7.5% | 649−5.6%7.4% | 634—7.5% | 618—6.8% | 680—7.3% | 688—7.3% | |
| Other current assets | 176—1.9% | 176+11.2%1.9% | 152−2.7%1.7% | 164+3.7%1.9% | 166—1.9% | 158—1.8% | 156−10.9%1.7% | 158—1.8% | — | — | 175—1.9% | — | — | |
| Current assets | 3,843—41.9% | 3,843+10.0%41.9% | 3,668−4.1%40.7% | 3,421−14.4%38.9% | 3,209−15.3%37.6% | 3,494−0.0%40.0% | 3,823−8.6%41.8% | 3,997−7.9%45.0% | 3,789−10.0%43.5% | 3,494—41.3% | 4,185—45.8% | 4,339—46.5% | 4,211—44.6% | |
| Property, plant and equipment | 568—6.2% | 568+5.8%6.2% | 560+4.1%6.2% | 571+7.9%6.5% | 556+5.9%6.5% | 537+1.9%6.2% | 538+4.0%5.9% | 529+7.2%5.9% | 525+5.4%6.0% | 527—6.2% | 517—5.7% | 493—5.3% | 498—5.3% | |
| Right-of-use (leased) assets | — | — | 94+2.1%1.0% | — | — | — | 92+47.0%1.0% | — | — | — | 63—0.7% | — | — | |
| Goodwill | 3,645—39.7% | 3,645+6.5%39.7% | 3,641+5.7%40.4% | 3,644+10.7%41.4% | 3,624+10.1%42.4% | 3,423+3.5%39.2% | 3,443+4.9%37.6% | 3,291−0.2%37.0% | 3,292−0.1%37.8% | 3,306—39.0% | 3,281—35.9% | 3,298—35.3% | 3,297—34.9% | |
| Other intangible assets | 547—6.0% | 547−31.0%6.0% | 589−30.3%6.5% | 642−6.6%7.3% | 674−10.4%7.9% | 793−4.7%9.1% | 845−5.0%9.2% | 688−26.9%7.7% | 752−37.5%8.6% | 833—9.8% | 889—9.7% | 940—10.1% | 1,202—12.7% | |
| Long-term investments | — | — | 0−100%0.0% | 0—0.0% | 0—0.0% | 48—0.5% | 96—1.1% | — | — | — | 0—0.0% | — | — | |
| Total assets | 9,181—100% | 9,181+5.2%100% | 9,015−1.5%100% | 8,806−0.9%100% | 8,545−1.9%100% | 8,729+3.1%100% | 9,156+0.2%100% | 8,890−4.8%100% | 8,714−7.8%100% | 8,470—100% | 9,139—100% | 9,338—100% | 9,449—100% | |
| Accounts payable | 201—2.2% | 201−15.0%2.2% | 193−5.1%2.1% | 193−4.6%2.2% | 209+3.0%2.4% | 237+28.8%2.7% | 204+16.3%2.2% | 202+11.8%2.3% | 203+8.1%2.3% | 184—2.2% | 175—1.9% | 181—1.9% | 187—2.0% | |
| Debt due within a year | 5.8—0.1% | 5.8−87.6%0.1% | 2.9−92.3%0.0% | 0−100%0.0% | 56+50.3%0.7% | 47+25.1%0.5% | 38−86.9%0.4% | 38+17.9%0.4% | 37+42.7%0.4% | 37—0.4% | 287—3.1% | 32—0.3% | 26—0.3% | |
| Current liabilities | 951—10.4% | 951−5.1%10.4% | 977−5.8%10.8% | 963−4.0%10.9% | 990+3.7%11.6% | 1,002+11.5%11.5% | 1,037−14.1%11.3% | 1,002+2.2%11.3% | 955−0.0%11.0% | 899—10.6% | 1,207—13.2% | 981—10.5% | 955—10.1% | |
| Long-term debt | 2,503—27.3% | 2,503+1.0%27.3% | 2,505+0.3%27.8% | 2,509+0.1%28.5% | 2,461−2.1%28.8% | 2,479−1.7%28.4% | 2,497−1.3%27.3% | 2,506−10.2%28.2% | 2,514−10.1%28.8% | 2,523—29.8% | 2,531—27.7% | 2,789—29.9% | 2,798—29.6% | |
| Lease liabilities (non-current) | — | — | 79−5.4%0.9% | — | — | — | 84+78.1%0.9% | — | — | — | 47—0.5% | — | — | |
| Retained earnings | 3,591—39.1% | 3,591+17.8%39.1% | 3,412+19.9%37.8% | 3,224+20.9%36.6% | 3,029+22.5%35.5% | 3,047+32.3%34.9% | 2,846+38.4%31.1% | 2,667+35.7%30.0% | 2,473+23.3%28.4% | 2,303—27.2% | 2,056—22.5% | 1,966—21.1% | 2,006—21.2% | |
| Shareholders' equity | 5,245—57.1% | 5,245+9.9%57.1% | 5,048−1.6%56.0% | 4,843−2.2%55.0% | 4,619−4.7%54.1% | 4,773+2.6%54.7% | 5,130+2.3%56.0% | 4,951−4.5%55.7% | 4,844−8.6%55.6% | 4,654—54.9% | 5,017—54.9% | 5,182—55.5% | 5,301—56.1% | |
| Total equity | 5,245—57.1% | 5,245+9.9%57.1% | 5,048−1.6%56.0% | 4,843−2.2%55.0% | 4,619−4.7%54.1% | 4,773+2.6%54.7% | 5,130+2.3%56.0% | 4,951−4.5%55.7% | 4,844−8.6%55.6% | 4,654—54.9% | 5,017—54.9% | 5,182—55.5% | 5,301—56.1% | |
| Total liabilities and equity | 9,181—100% | 9,181+5.2%100% | 9,015−1.5%100% | 8,806−0.9%100% | 8,545−1.9%100% | 8,729+3.1%100% | 9,156+0.2%100% | 8,890−4.8%100% | 8,714−7.8%100% | 8,470—100% | 9,139—100% | 9,338—100% | 9,449—100% | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 296+0.3%7.2% | 70−5.9%6.6% | 80*+6.6%7.6% | 70−2.9%6.9% | 76+3.4%7.6% | 74−16.3%7.2% | 75*−1.2%7.6% | 72−11.0%7.1% | 74−8.8%7.2% | 88—8.7% | 76*—8.0% | 81—8.2% | 81—7.9% | |
| Share-based compensation | 81−3.1%2.0% | 27−10.6%2.6% | 12*−6.8%1.2% | 14−7.5%1.3% | 28+10.1%2.8% | 30+4.9%2.9% | 13*−30.5%1.3% | 15−13.6%1.4% | 26+11.2%2.5% | 29—2.8% | 19*—2.0% | 17—1.7% | 23—2.3% | |
| Cash from operating activities | 1,098−12.5%26.6% | 230+21.4%21.9% | 355*−3.2%33.8% | 343*−15.4%33.5% | 169*−42.1%16.9% | 189−14.0%18.5% | 367*+41.9%37.1% | 406*+21.9%40.1% | 292*+41.7%28.7% | 220—21.7% | 259*—27.4% | 333*—33.8% | 206*—20.1% | |
| Capital expenditure | −104—−2.5% | −15—−1.4% | −14*—−1.3% | −35—−3.4% | −40—−4.0% | −17—−1.6% | −16*—−1.7% | −34—−3.4% | −28—−2.8% | −23r−38—−2.2% | −36*—−3.8% | −37—−3.7% | −32—−3.1% | |
| Intangible assets bought | 0—0.0% | 0—0.0% | 0*—0.0% | 0*—0.0% | 0*—0.0% | −15—−1.5% | 0*—0.0% | −10*—−1.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | — | — | |
| Acquisitions, net of cash acquired | — | — | 0*—0.0% | — | −323*—−32.1% | −0.3—−0.0% | −297*—−30.1% | 0*—0.0% | 0*—0.0% | 0—0.0% | −3.2*—−0.3% | −1.8*—−0.2% | 0*—0.0% | |
| Cash from investing activities | −473—−11.5% | −12—−1.2% | −132*—−12.6% | −4.3*—−0.4% | −324*—−32.3% | −22—−2.2% | −596*—−60.3% | −43*—−4.2% | −39*—−3.8% | −104—−10.3% | −56*—−5.9% | −39*—−3.9% | −16*—−1.6% | |
| Debt repaid | — | 0—0.0% | — | −9.3*—−0.9% | −9.4*—−0.9% | −9.4—−0.9% | — | −9.3*—−0.9% | −9.4*—−0.9% | −259—−25.6% | — | −3.8*—−0.4% | −3.7*—−0.4% | |
| Shares bought back | −236—−5.7% | 0—0.0% | 0*—0.0% | −36*—−3.5% | −200*—−19.9% | −517—−50.6% | −58*—−5.9% | −100*—−9.9% | 0*—0.0% | −677—−66.8% | −211*—−22.3% | −114*—−11.5% | −50*—−4.9% | |
| Cash from financing activities | −251—−6.1% | −11—−1.0% | 1.6*—0.2% | −40*—−3.9% | −202*—−20.1% | −537—−52.6% | −57*—−5.7% | −104*—−10.3% | −4.2*—−0.4% | −944—−93.2% | −211*—−22.3% | −110*—−11.1% | −50*—−4.8% | |
| Exchange-rate effect on cash | 12—0.3% | 1.4—0.1% | −0.3*−105%−0.0% | 6.8*—0.7% | 4.0*—0.4% | −8.4−291%−0.8% | 6.6*—0.7% | −0.3*—−0.0% | −1.8*−460%−0.2% | 4.4—0.4% | −1.4*—−0.1% | −1.7*—−0.2% | 0.5*—0.0% | |
| Change in cash | 386—9.4% | 209—19.9% | 224*—21.4% | 306*+18.0%29.9% | −353*−242%−35.1% | −378—−37.0% | −279*—−28.2% | 259*+41.7%25.6% | 248*+75.9%24.4% | −824—−81.3% | −9.3*—−1.0% | 183*—18.6% | 141*—13.7% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Dec 27, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Hologic, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product(total)$3.3 B79%+0.0%
- Disposables$2.6 B64%+5.1%
- Molecular Diagnostics$1.3 B32%+3.0%
- Breast Imaging$1.1 B27%-8.4%
- Service(total)$844 M21%+8.9%
- Capital equipment, components and software$638 M16%-17%
- Cytology & Perinatal$489 M12%+2.0%
- Interventional Breast Solutions$375 M9.1%+20%
- Blood Screening$28 M0.7%-6.9%
- Other$19 M0.5%+11%
Business segments
- Diagnostics$1.8 B45%+2.5%
- Breast Health$1.5 B36%-2.5%
- GYN Surgical$680 M17%+6.0%
- Skeletal Health$109 M2.7%+30%
Countries and regions
- 🇺🇸 USA$3.0 B74%+0.8%
- International$1.1 B26%+4.6%
- Europe$591 M14%+11%
- Asia-Pacific$243 M5.9%-6.3%
- Rest of World$218 M5.3%+2.1%
Source: SEC annual report (XBRL data) · as of Sep 27, 2025
Where Hologic, Inc. operates: 31 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 78 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters3 offices19 subsidiaries | $3.0 B74% |
| 🇬🇧 UK | 9 subsidiaries | — |
| 🇧🇪 Belgium | 2 subsidiaries | — |
| 🇨🇳 China | 5 subsidiaries | — |
| 🇩🇪 Germany | 4 subsidiaries | — |
| 🇧🇲 Bermuda | 3 subsidiaries | — |
| 🇫🇮 Finland | 3 subsidiaries | — |
| 🇳🇱 Netherlands | 3 subsidiaries | — |
| 🇨🇭 Switzerland | 3 subsidiaries | — |
| 🇩🇰 Denmark | 2 subsidiaries | — |
| 🇫🇷 France | 2 subsidiaries | — |
| 🇭🇰 Hong Kong | 2 subsidiaries | — |
| 🇪🇸 Spain | 2 subsidiaries | — |
| 🇸🇪 Sweden | 2 subsidiaries | — |
| 🇦🇺 Australia | 1 subsidiary | — |
| 🇦🇹 Austria | 1 subsidiary | — |
| 🇧🇷 Brazil | 1 subsidiary | — |
| 🇻🇬 British Virgin Islands | 1 subsidiary | — |
| 🇨🇦 Canada | 1 subsidiary | — |
| 🇨🇷 Costa Rica | 1 subsidiary | — |
| 🇮🇳 India | 1 subsidiary | — |
| 🇮🇪 Ireland | 1 subsidiary | — |
| 🇮🇹 Italy | 1 subsidiary | — |
| 🇯🇵 Japan | 1 subsidiary | — |
| 🇲🇾 Malaysia | 1 subsidiary | — |
| 🇳🇴 Norway | 1 subsidiary | — |
| 🇵🇹 Portugal | 1 subsidiary | — |
| 🇸🇦 Saudi Arabia | 1 subsidiary | — |
| 🇸🇬 Singapore | 1 subsidiary | — |
| 🇰🇷 South Korea | 1 subsidiary | — |
| 🇹🇼 Taiwan | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Events at Hologic, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Taken over and delisted 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 11 · Material agreement 3 · Agreement ended 1 · New debt 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 11
| Filed | What happened | Filing |
|---|---|---|
| Taken over and delistedChange in controlAcquisition or sale completedDirectors and officersMaterial agreementAgreement endedShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersMaterial agreement | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K/A | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Apr 7, 2026
Acquisitions and funding#
4 acquisitions, $669 M paid where reported
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| Gynesonics, Inc | 2025 | — | $341 M | — | Annual report |
| Endomagnetics Ltd | 2024 | — | $314 M | — | Annual report |
| Normedi | 2023 | — | $8 M | — | Annual report |
| JW Medical | 2023 | — | $7 M | — | Annual report |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Government contracts: Hologic, Inc.#
$3.5 M in federal contracts in fiscal 2026, mostly from Department of Veterans Affairs and Department of Defense.
- Department of Veterans Affairs$3.1 M
- Department of Defense$441 K
| Fiscal year | Contracts | Grants |
|---|---|---|
| FY2027 (to date) | $63 K | — |
| FY2026 | $3.5 M | — |
| FY2025 | $6.1 M | — |
| FY2024 | $20.9 M | — |
| FY2023 | $37.4 M | — |
| FY2022 | $74.2 M | — |
| FY2021 | $165.8 M | — |
| FY2020 | $65.0 M | — |
| FY2019 | $23.7 M | — |
| FY2018 | $29.9 M | — |
| FY2017 | $37.6 M | — |
| FY2016 | $37.1 M | — |
| FY2015 | $29.8 M | — |
| FY2014 | $33.8 M | — |
| FY2013 | $18.6 M | — |
| FY2012 | $18.0 M | — |
| FY2011 | $14.0 M | — |
| FY2010 | $23.0 M | — |
| FY2009 | $18.5 M | — |
| FY2008 | $25.3 M | — |
Source: USAspending.gov. Obligations are binding promises to pay, not payments, and can be negative when an award is cut. Counted under Hologic, Inc.: HOLOGIC, INC. (UEI WHWJBKU5SX73)
Lobbying by Hologic, Inc.#
$1.2 M spent on lobbying the US Congress and federal agencies in 2025, most often on health issues, trade (domestic/foreign) and manufacturing.
- Health Issues8 reports
- Trade (domestic/foreign)3 reports
- Manufacturing2 reports
- Budget/Appropriations2 reports
- Medicare/Medicaid1 report
Lobbying firms hired in 2025
ALSTON & BIRD LLP $620 K
The firms' fees are part of Hologic, Inc.'s own reported expenses, so they are not added again.
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $930 K | $930 K | 6 |
| 2025 | $1.2 M | $1.2 M | 8 |
| 2024 | $1.0 M | $1.0 M | 10 |
| 2023 | $1.1 M | $1.1 M | 12 |
| 2022 | $1.0 M | $1.0 M | 21 |
| 2021 | $400 K | — | 16 |
| 2020 | $290 K | — | 12 |
| 2019 | $310 K | — | 10 |
| 2018 | $240 K | — | 8 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Hologic, Inc.”, “Capitol Counsel LLC on behalf of Hologic, Inc.” and “Burson Cohn & Wolfe on behalf of Hologic, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Hologic, Inc.#
32 labor condition applications certified in fiscal 2026 for 32 positions, at a median wage of $140 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Electrical Engineer 3Electrical Engineers | 2 | $148 K |
| Lead Design Assurance EngineerValidation Engineers | 2 | $165 K |
| Quality Engineer 2Validation Engineers | 2 | $106 K |
| Demand Planner 3Transportation, Storage, and Distribution Managers | 1 | $106 K |
| Lead Software Design Assurance EngineerSoftware Quality Assurance Analysts and Testers | 1 | $155 K |
| Lead Software Engineer, Full StackSoftware Developers | 1 | $165 K |
| Lead Systems Engineer, R&DElectrical Engineers | 1 | $158 K |
| Lead Ultrasound EngineerBioengineers and Biomedical Engineers | 1 | $140 K |
| Manager, Software EngineeringSoftware Developers | 1 | $163 K |
| Medical Device Reporting SpecialistRegulatory Affairs Specialists | 1 | $106 K |
Where: Newark, DE 16 · Marlborough, MA 12 · Louisville, CO 1 · Killeen, TX 1 · Ellicott City, MD 1 · Denville, NJ 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 32 | 32 | $140 K | 32 |
| FY2025 | 31 | 31 | $121 K | 31 |
| FY2024 | 21 | 21 | $120 K | 21 |
| FY2023 | 14 | 14 | $130 K | 15 |
| FY2022 | 34 | 34 | $125 K | 34 |
| FY2021 | 27 | 27 | $105 K | 27 |
| FY2020 | 20 | 20 | $118 K | 21 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Hologic, Inc.
Product recalls by Hologic, Inc.#
36 recalls since 2015, 847,509 units in the notices that give a number. Medical devices (FDA): 36.
| Date | What and why | Units | Notice |
|---|---|---|---|
| SELENIA DIMENSIONS MAMMOGRAPHY SYSTEMS. Model Numbers: SDA-SYS-3000-2D-HTC, SDA-SYS-3000-3D, SDM-SYS-6000-2D, SDM-SYS-6000-3D, SDM-00001-2D, SDM-00001-3D, SDM-00001-M2D, SDM-00001-M3D, SDM-05000-2A2, SDM-05000-2A3, SDM-05000-2AC, SDM-05000-2D2, SDM-05000-2D3, SDM-05000-2DC, SDM-05000-3D2, SDM-05000-3D3, SDM-05000-3DC, SDM-SYS-9… (and 1 more products)Complaints have been received of systems developing loose, missing, or broken internal bolts over time.Medical devicesClass II | 4,305 | Z-2167-2026 | |
| Brand Name: Genius" Review Station Product Name: Genius" Review Station Display (Barco Monitor) Model/Catalog Number: CMP-01669 Software Version: N/A - not software version specific Component: Yes, the Genius" Review Station is a component of the Genius" Digital Diagnostics System with the Genius" Cervical AI Algorithm cleared…It was identified that certain devices were being operated outside the validated and FDA-cleared display configuration due to user modification of the manufacturer-installed settings. Modifications included disabling Barco Application Appearance Manager (AAM), altering calibration and compliance parameters, and adjusting additional display-related settings. This field correction is being conducted to restore affected system to the validated configuration and reinforce proper use in accordance with the Operator's Manual.Medical devicesClass II | 1,200 | Z-1949-2026 | |
| Brand Name: Aptima HPV Assay Product Name: Aptima HPV Assay Model/Catalog Number: 303585 Product Description: Aptima HPV assay Component: NoDue to product exhibiting potential to generate either invalid or false negative results.Medical devicesClass II | 306 | Z-1586-2026 | |
| Brevera Breast Biopsy System Disposable 9 Gauge Needle. Biopsy Instrument.Presence of particulates in affected devices that can be deposited into breast tissue during use.Medical devicesClass II | 681,870 | Z-1314-2026 | |
| ThinPrep¿ CytoLyt¿ Solution. Buffered Cell Wash Solution.Fungal contamination of affected lot with Parengyodontium album.Medical devicesClass II | 3,728 | Z-1093-2026 | |
| Brand Name: Sertera Biopsy Device Product Name: Sertera Biopsy Device Model/Catalog Number: Sertera-14 Software Version: N/A Product Description: Instrument, Biopsy Component: N/ADevices presented a condition in which the inner needle separated from the hub and produced a longer throw of the inner needle or dislodgement.Medical devicesClass II | 55,335 | Z-1170-2025 | |
| The Rapid fFN Specimen Collection Tube (PN: 71550-001) is a component of the Rapid fFN Specimen Collection kit (PN: 71738-001). The Collection Tube (PN: 71550-001) is manufactured by a third-party supplier, MML Diagnostics Packaging, and includes the transport tube, cap, and extraction buffer. Tubes are packaged into PN: 71738-…Three lots of Rapid fFN Specimen Collection kit (901164, 901165, and 904850) contain Rapid fFN Specimen Collection Tubes which may be empty, underfilled, or overfilled with extraction buffer. The transport tubes are used with the Fetal Fibronectin Enzyme Immunoassay and Rapid fFN¿ for the TLiIQ¿ System which aids in assessing the risk of preterm delivery. The use of empty transport tubes or transport tubes containing insufficient extraction buffer volume may result in invalid results and/or delays in obtaining results. Additionally, the use of underfilled tubes may result in false positive results and the use of overfilled tubes may result in false negative results.Medical devicesClass II | 1,351 | Z-1095-2025 | |
| Panther Fusion GBS Assay REF PRD-04484 Kit containing Panther Fusion GBS Reagent Cartridge IVD.Potential weak pouch seal on Panther Fusion GBS assay cartridge, causing potential for invalid or incorrect results leading to a possible delay of treatment.Medical devicesClass II | 380 | Z-0907-2025 | |
| Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay, REF: PRD-07400SARS-CoV-2/Flu A/B/RSV Assay Kit may erroneously produce SARS-CoV-2 false positive results.Medical devicesClass II | 3 | Z-0694-2025 | |
| BioZorb Marker. Radiographic soft tissue marker.Firm received reports of adverse events/complications that include serious injuries, such as pain, infection, rash, device migration, device erosion, seroma, and discomfort.Medical devicesClass I | 12,710 | Z-0328-2025 | |
| Selenia Dimensions/ 3Dimensions-Digital breast tomosynthesis Software Version Dimensions 1.12.0 and 3Dimensions 2.3.0 system software as follows Model/Catalog Number: 1. ASY-16824 FMI UPGRADE KIT, DIMENSIONS 1.12.0.3 SYSTEM SOFTWARE UPGRADE FOR 1.11.1 SYSTEMS 2. ASY-16825 FMI UPGRADE KIT, 3DIMENSIONS 2.3.0.3 SYSTEM SOFTWARE UPG…Identified an issue with Selenia Dimensions 1.12.0 and 3Dimensions 2.3.0 system software when used in combination with C-View software in which the quality of the final C-View synthesized 2D image is impacted and may appear blurry and result in misdiagnosis with the possibility being a false negative diagnosisMedical devicesClass II | 425 | Z-3248-2024 | |
| Horizon X-Ray Bone Densitometer (DXA) Models: Horizon-A, Horizon-W, Horizon-WI, Horizon-C, Horizon-CI, Horizon-A-CN, Horizon-W-CN, Horizon-WI-CN, Horizon-CI-CNNon-conformance pertains to electromagnetic compatibility requirements according to the international technical standard IEC 60601-1-2 for the safety and essential performance of medical electrical equipment, where the result from the Horizon DXA System exceeded the limit for acceptability.Medical devicesClass II | 2,642 | Z-2373-2024 | |
| BioZorb Marker-BioZorb 3D Bioabsorbable Marker-Intended Use radiographic marking of sites in soft tissue. 1) F0405 BioZorb Marker 4cm x 5cm 2) F0404 BioZorb Marker 4cm x 4cm 3) F0331 BioZorb Marker 1cm x 3cm x 3cm 4) F0231 BioZorb Marker 1cm x 3cm x 2cm 5) F0221 BioZorb Marker 1cm x 3cm x 2cm 6) F0304 BioZorb Marker 3cm x 4cm 7…Safety Information: Complaints describe complications/adverse events that include pain, infection, rash, device migration, device erosion, seroma, discomfort, or other complications from feeling the device in the breast, and the need for additional medical treatment to remove the deviceMedical devicesClass I | 53,492 | Z-1733-2024 | |
| PANTHER FUSION System REF 9121010000 The Panther System is an integrated nucleic acid testing system which fully automates all steps necessary to perform Aptima assays from sample processing through amplification, detection, and data reduction. The Panther Fusion System is an integrated, fully automated, in vitro diagnostic (IV…Due to potential false positive Flu B results when a sample was also SARS-CoV-2 positive.Medical devicesClass II | 771 | Z-0782-2024 | |
| Aptima CMV Quant Assay, Reference numbers: AW-22600-001, AW-25509-001, and AW-26381-001 Amplification Reagent, Enzyme Reagent, Promoter Reagent, Amplification Reconstitution Solution, Enzyme Reconstitution Solution, Promoter Reconstruction solution, Target capture Reagent, Reconstitution Collars.Use of assay along with plasma specimen may result in error code which would invalidate sample.Medical devicesClass II | 684 | Z-1371-2024 | |
| Sertera 14 Gauge Biopsy Device-intended to obtain percutaneous core biopsy samples from soft tissue and tumors of the breast REF: SERTERA-14The inner needle of the Sertera device is either detaching or discharging and may cause delay in surgeryMedical devicesClass II | 756 | Z-2035-2023 | |
| Hologic 3Dimensions/Selenia Dimensions Models: RM-SDM-00001-3D SDM-00001-2D SDM-00001-3D SDM-05000-3D3 SDM-05000-2DC SDM-00001-M3D SDM-05000-3DC SDM-SYS-6000-3D SDM-05000-2D3 SDA-SYS-3000-2D SDM-00001 SDM-SYS-9000-2D SDM-00001-M2D 3DM-SYS-STD 3DM-SYS-STD-NS SDM-05000-2AC SDM-05000-2A2 SDA-SYS-3000-3D SDA-SYS-3000-3D-UPS SDM-SYS…C-Arm unexpected movement may cause blunt trauma should the tube arm impinge upon an individualMedical devicesClass II | 797 | Z-1144-2023 | |
| Hologic Sizer Set- sterilization tray and 6 individual sizers, intended as a Surgical instrument guide Model/Catalog Number: F0101IFU was not provided with the Sizer Set sterilization tray Revised Sterilization Instructions for Sizer SetMedical devicesClass II | 178 | Z-0669-2025 | |
| The BioZorb LP Marker is an implantable radiopaque marker used to facilitate visualization of a soft tissue site. The BioZorb LP Marker is comprised of a bioabsorbable PLA (polylactic acid) component which resorbs completely in 1 year or more and a permanent component (titanium). The BioZorb LP Marker is provided sterile for si…Hologic BioZorb LP Marker, (Product number F0221), lot number 22A0RL, contained removable labels with an expiration date that indicated the product had already expired. The expiration date on the removable label is actually manufacturing date, and it's different from the one on the shelf box label, which is the correct expiration date.Medical devicesClass II | 233 | Z-1858-2022 | |
| Panther Fusion GBS Assay Cartridges 96 Tests, Catalog Number: PRD-04484. in vitro diagnostic test for group b streptococcus.Samples, run on a GBS Assay, that have analyte concentrations that are at or near the limit of detection may produce false negative results.Medical devicesClass II | 2,061 | Z-0877-2022 | |
| Panther Fusion Extraction Reagent-X, REF PRD-04477, For use with Panther Fusion System, IVD, Rx only, Contents: FCR-X Fusion Capture reagent-X 4 EA, FER-X Fusion Enhancer Reagent-X (Lithium Hydroxide Solution) 4 EAFailed stability specifications for reagent kits that may result in false negative test results.Medical devicesClass II | 264 | Z-0750-2022 | |
| Panther Fusion Tube Tray, REF PRD-04000, PN: FA-15004, Cont. 18 Tube Trays - Product Usage: an ancillary consumable to the Panther Fusion System that is used to contain the PCR and RT-PCR steps of the assay processing.There is a potential for tube trays to leak which could potentially result in false positive results, false negative results or invalid patient results.Medical devicesClass II | 1,355 | Z-1369-2021 | |
| Panther Fusion Tube Tray, Part: FAB-15004, REF: PRD-04000Tube trays may leak which could invalidate patient results or assay worklists, causing delayed results for any assays with which they are used. A possibility exists of false negative result with flu A/B/RSV assay or paraflu assay.Medical devicesClass II | 607 | Z-2990-2020 | |
| Selenia Dimensions Mammography System, Model number ASY-04160, Selenia Dimensions Gantry, UDI 15420045505636,The recalling firm has received reports from the field of the C-arm on the Selenia Dimensions system seizing or dropping during field repairs and cleaning of the systems.Medical devicesClass II | 72 | Z-1343-2020 | |
| Panther Fusion Extraction Reagent-S, Ref PRD-04331, IVD, CE, Rx Only consisting of FCR-S Fusion Capture Reagent - S, Nucleic Acid in a buffered solution and FER-S Fusion Enhancer Reagent-S (Lithium Hydroxide Solution), UDI: 15420045509214Reagent component included in flu test kit may cause both high background signal in a true negative sample leading to false positive and/or false negative results. This could result in false positive and/or false negative results on patient samples or failed controls leading to invalid runs. This could result in incorrect results being reported and a delay in treatment.Medical devicesClass II | 47 | Z-2163-2020 | |
| I-View¿ Contrast Enhanced Digital Mammography, ASY-08109Calibration issue not possible to visualize contrast uptake in the subtracted mammography imagesMedical devicesClass II | 337 | Z-0685-2019 | |
| Hologic Panther(R) Fusion(TM), Catalog number ASY-09600 Product Usage: The Panther instrument is a fully automated sample-to-result instrument, eliminating the need for batch processing and automates all aspects of nucleic acid testing on a single, integrated platform. The Panther can be test samples with random access or batch…The Panther or the Panther Fusion glass panel separates from the 19 inch touch screen monitor and could potentially fall and hit an operator.Medical devicesClass II | 103 | Z-0595-2018 | |
| Rapid for the TLiIQ(R) System, HOLOGIC(R), Catalog number: 01200 (and 1 more products)Rapid fFN cassettes were manufactured with material (A137 ascites) from a new supplier (SDIX). The products were distributed to customers before FDA approved the change to use the material from SDIX.Medical devicesClass II | 165 | Z-0676-2018 | |
| Panther(R) System, Catalog Number 902615, For Use with Hologic Assays, For In Vitro Diagnostic UseAn incorrect incubator was installed on one Panther System which potentially led to incorrect Aptima Combo 2(R) assay (AC2) results.Medical devicesClass II | 1 | Z-0027-2018 | |
| Affirm Lateral Arm Upright Biopsy Accessory. Product Number: ASY-09880The firm is implementing a product correction involving its Affirm¿ Lateral Arm Upright Biopsy Accessory, ASY-09880. The correction has been initiated due to a component (the Left-hand Guide or the Blue Needle Guide) issue that could impact needle alignment for all the left-approach lateral biopsy procedures. This may have an impact on the position of the needle within the breast, and thus on the aspiration of the intended tissue. This impact is case-dependent and detectable when imagining is used to confirm needle position and/or tissue acquisition during and after a procedure. There are no known instances of illness or injury.Medical devicesClass II | 12 | Z-0351-2018 | |
| Tomcat Instrument, REF ASY-07379, Hologic Incorporated, automated laboratory sample processing instrument.A Tomcat Instrument software anomaly that causes the pipettor arm to make physical contact with the mucous shelf which could potentially lead to incorrect patient results.Medical devicesClass II | 164 | Z-2864-2017 | |
| SURESOUND22US Multipack (US Distribution) containing 2 packs of six devices. SURESOUND22 Multipack (OUS Distribution) containing 2 packs of six devices. For uterine soundBreach in sterile barrier compromising product sterilityMedical devicesClass II | 600 | Z-0655-2017 | |
| Sertera Biopsy Device, Sterile; Used primarily in ultrasound-guided breast biopsies.Incorrect label on the Sertera Biopsy KitMedical devicesClass II | 570 | Z-2869-2016 | |
| SureSight Obturator Introducer Localization Systems (ILS) for ATEC in MRI. ILS-0914-12-OB (9G Introducer Localization Set (OB Model) for ATEC0914-12MR Handpiece Product Usage: The Sure Sight Obturator Introducer Localization System (ILS-OB) is a Hologic accessory kit. It is sold as an independent product for use with the ATEC M… (and 1 more products)Tip Breakage at the glue joint between the obturator body and tipMedical devicesClass II | 535 | Z-2766-2016 | |
| ATEC CANISTER. Suction Canister with Lid 490 cc., RX Only; Suction canister used to collect fluid during a breast biopsy.Cracks ATEC Canister Lids.Medical devicesClass II | 16,870 | Z-2239-2016 | |
| Hologic InPlex CF Molecular Test (IVD); Catalog Number: 95-432. (and 1 more products)Complaints of false positive HET mutations and leaking cards; could lead to unnecessary invasive testing during pregnancy and the associated risks of such invasive testing.Medical devicesClass II | 2,580 | Z-1580-2016 |
Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020 | · | · | · | 93 | · | · | · | · | · | · | · | · | 93 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| effective | 93 people | Layoff, temporaryWARN notice | San Diego County, California | Notice list |
Source: State WARN notices and SEC 8-K item 2.05
How Hologic, Inc. compares in Medical Instruments
- Revenue$4.1 B · higher than 89% of 120
- Net margin13.2% · higher than 65% of 114
- Revenue growth1.7% · higher than 21% of 49
- 🇺🇸 The Cooper Companies, Inc.$11.3 B
- 🇩🇪 Sartorius Stedim Biotech S.A.$22.0 B
- 🇩🇰 Coloplast A/S$15.4 B
- 🇸🇪 Getinge AB$7.0 B
- 🇯🇵 Ship Healthcare Holdings, Inc.$1.4 B
- 🇺🇸 Dentsply Sirona Inc.$1.9 B
Peer comparison · Medical Instruments
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Hologic, Inc.🇺🇸 | $16.9 B | — | 13.2% | +1.7% |
| Intuitive Surgical, Inc.🇺🇸 | $155.6 B | 52.6× | 25.5% | +20.5% |
| EssilorLuxottica S.A.🇫🇷 | $88.0 B | 32.1× | 8.1% | +4.5% |
| HOYA Corporation🇯🇵 | $56.2 B | 32.8× | 25.4% | — |
| Becton, Dickinson and Company🇺🇸 | $54.0 B | 57.4× | 4.2% | +8.2% |
| Alcon Inc.🇨🇭 | $37.1 B | 37.9× | 9.4% | +4.9% |
| ResMed Inc.🇺🇸 | $35.3 B | 22.1× | 27.8% | +9.8% |
| West Pharmaceutical Services, Inc.🇺🇸 | $27.1 B | 42.4× | 18.8% | +6.3% |
| Terumo Corporation🇯🇵 | $24.9 B | 27.0× | 12.0% | — |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Intuitive Surgical, Inc.$155.6 B
- EssilorLuxottica S.A.$88.0 B
- HOYA Corporation$56.2 B
- Becton, Dickinson and Company$54.0 B
- Alcon Inc.$37.1 B
- ResMed Inc.$35.3 B
Sources and freshness
- Market cap:
- Mar 8, 2026 (last known)
- Annual results:
- For year ending September-2025
- Balance sheet:
- As of September-2025
- Employees:
- As on 2022
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research, Wikipedia, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Hologic, Inc.? Verify and update this profile — free
Show Hologic, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.